Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma
© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd..
BACKGROUND: Overall survival is considered as one of the most important endpoints of treatment efficacy but often requires long follow-up. This study aimed to determine the validity of recurrence-free survival as a surrogate endpoint for overall survival in patients with surgically resectable advanced oesophageal squamous cell carcinoma (OSCC).
METHODS: Patients with OSCC who received neoadjuvant cisplatin and 5-fluorouracil, or docetaxel, cisplatin and 5-fluorouracil, at 58 Japanese oesophageal centres certified by the Japan Esophageal Society were reviewed retrospectively. The correlation between recurrence-free and overall survival was assessed using Kendall's τ.
RESULTS: The study included 3154 patients. The 5-year overall and recurrence-free survival rates were 56.6 and 47.7% respectively. The primary analysis revealed a strong correlation between recurrence-free and overall survival (Kendall's τ 0.797, 95% c.i. 0.782 to 0.812) at the individual level. Subgroup analysis showed a positive relationship between a more favourable pathological response to neoadjuvant chemotherapy and a higher τ value. In the meta-regression model, the adjusted R2 value at the institutional level was 100 (95% c.i. 40.2 to 100)%. The surrogate threshold effect was 0.703.
CONCLUSION: There was a strong correlation between recurrence-free and overall survival in patients with surgically resectable OSCC who underwent neoadjuvant chemotherapy, and this was more pronounced in patients with a better response to neoadjuvant chemotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:111 |
|---|---|
| Enthalten in: |
The British journal of surgery - 111(2024), 2 vom: 31. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Okui, Jun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 22.02.2024 Date Revised 22.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/bjs/znae038 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368674037 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368674037 | ||
| 003 | DE-627 | ||
| 005 | 20240222232737.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/bjs/znae038 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1302.xml |
| 035 | |a (DE-627)NLM368674037 | ||
| 035 | |a (NLM)38377361 | ||
| 035 | |a (PII)znae038 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Okui, Jun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2024 | ||
| 500 | |a Date Revised 22.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd. | ||
| 520 | |a BACKGROUND: Overall survival is considered as one of the most important endpoints of treatment efficacy but often requires long follow-up. This study aimed to determine the validity of recurrence-free survival as a surrogate endpoint for overall survival in patients with surgically resectable advanced oesophageal squamous cell carcinoma (OSCC) | ||
| 520 | |a METHODS: Patients with OSCC who received neoadjuvant cisplatin and 5-fluorouracil, or docetaxel, cisplatin and 5-fluorouracil, at 58 Japanese oesophageal centres certified by the Japan Esophageal Society were reviewed retrospectively. The correlation between recurrence-free and overall survival was assessed using Kendall's τ | ||
| 520 | |a RESULTS: The study included 3154 patients. The 5-year overall and recurrence-free survival rates were 56.6 and 47.7% respectively. The primary analysis revealed a strong correlation between recurrence-free and overall survival (Kendall's τ 0.797, 95% c.i. 0.782 to 0.812) at the individual level. Subgroup analysis showed a positive relationship between a more favourable pathological response to neoadjuvant chemotherapy and a higher τ value. In the meta-regression model, the adjusted R2 value at the institutional level was 100 (95% c.i. 40.2 to 100)%. The surrogate threshold effect was 0.703 | ||
| 520 | |a CONCLUSION: There was a strong correlation between recurrence-free and overall survival in patients with surgically resectable OSCC who underwent neoadjuvant chemotherapy, and this was more pronounced in patients with a better response to neoadjuvant chemotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 700 | 1 | |a Nagashima, Kengo |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuda, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Yasunori |e verfasserin |4 aut | |
| 700 | 1 | |a Okamura, Akihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kawakubo, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Muto, Manabu |e verfasserin |4 aut | |
| 700 | 1 | |a Kakeji, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kono, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Hiroya |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Doki, Yuichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Bamba, Takeo |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuda, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Fujiwara, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Shinsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Noma, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Miyata, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Fujita, Takeo |e verfasserin |4 aut | |
| 700 | 1 | |a Kitagawa, Yuko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The British journal of surgery |d 1945 |g 111(2024), 2 vom: 31. Jan. |w (DE-627)NLM000001465 |x 1365-2168 |7 nnns |
| 773 | 1 | 8 | |g volume:111 |g year:2024 |g number:2 |g day:31 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/bjs/znae038 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 111 |j 2024 |e 2 |b 31 |c 01 | ||